

Focus on sexual health

Arousal and orgasmic dysfunction in women

By Brooke M. Faught, DNP, WHNP-BC, NCMP, IF, and Sue W. Goldstein, BA, CSE, CCRC, IF

References

1. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. Parish SJ, Goldstein AT, Goldstein SW, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions—part II. *J Sex Med*. 2016;13(12):1888-1906.
3. Parish SJ, Meston CM, Althof SE, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions—part III. *J Sex Med*. 2019;16(3):452-462.
4. McCabe MP, Sharlip ID, Atalla E, et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. *J Sex Med*. 2016;13(2):135-143.
5. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. Text revision. Washington, DC: American Psychiatric Association; 2000.
6. Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. *Obstet Gynecol*. 2008;112(5):970-978.
7. Perelman MA. The Sexual Tipping Point: a mind/body model for sexual medicine. *J Sex Med*. 2009;6(3):629-632.
8. Nappi RE, Cucinella L, Martella S, et al. Female sexual dysfunction (FSD): prevalence and impact on quality of life (QoL). *Maturitas*. 2016;94:87-91.
9. Rosen C, Brown J, Heiman S, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther*. 2000;26(2):191-208.
10. Derogatis LR, Rosen R, Leiblum S, et al. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. *J Sex Marital Ther*. 2002;28(4):317-330.
11. Goldey KL, van Anders SM. Sexy thoughts: effects of sexual cognitions on testosterone, cortisol, and arousal in women. *Horm Behav*. 2011;59(5):754-764.
12. Nappi RE, Detaddei S, Ferdeghini F, et al. Role of testosterone in feminine sexuality. *J Endocrinol Invest*. 2003;26(3 suppl):97-101.
13. Rastrelli G, Corona G, Maggi M. Testosterone and sexual function in men. *Maturitas*. 2018;112:46-52.
14. Davis SR, Bitzer J, Giraldo A, et al. Change to either a nonandrogenic or androgenic progestin containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive associated sexual dysfunction. *J Sex Med*. 2013;10(12):3069-3079.
15. Lee JJML, Tan TC, Ang SB. Female sexual dysfunction with combined oral contraceptive use. *Singapore Med J*. 2017;58(6):285-288.
16. Caruso S, Cicero C, Romano M, et al. Tadalafil 5 mg daily treatment for type 1 diabetic premenopausal women affected by sexual genital arousal disorder. *J Sex Med*. 2012;9(8):2057-2065.
17. Lee JJM, Low LL, Ang SB. Oral contraception and female sexual dysfunction in reproductive women. *Sex Med Rev*. 2017;5(1):31-44.
18. Haring R, Hannemann A, John U, et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. *J Clin Endocrinol Metab*. 2012;97(2):408-415.
19. Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. *J Clin Endocrinol Metab*. 2019;104(10):4660-4666.
20. Belkin ZR, Krapf JM, Goldstein AT. Drugs in early clinical development for the treatment of female sexual dysfunction. *Expert Opin Investig Drugs*. 2015;24(2):159-167.
21. Krychman ML, Kingsberg SA. Female sexual disorders: treatment options in the pipeline. *Formulary*. 2013;48(3).
22. Poels S, Bloemers J, van Rooij K, et al. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. *J Sex Med*. 2013;10(3):810-823.
23. Poels S, Bloemers J, van Rooij K, et al. Two novel combined drug treatments for women with hypoactive sexual desire disorder. *Pharmacol Biochem Behav*. 2014;121:71-79.
24. van der Made F, Bloemers J, Yassem WE, et al. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. *J Sex Med*. 2009;6(3):777-790.
25. van Rooij K, Poels S, Bloemers J, et al. Toward personalized sexual medicine (part 3): testosterone combined with a serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms. *J Sex Med*. 2013;10(3):824-837.
26. Bloemers J, van Rooij K, Poels S, et al. Toward personalized sexual medicine (part 1): integrating the “dual control model” into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder. *J Sex Med*. 2013;(3):791-809.
27. van Rooij K, de Leede L, Frijlink HW, et al. Pharmacokinetics of a prototype formulation of sublingual testosterone and a buspirone tablet, versus an advanced combination tablet of testosterone and buspirone in healthy premenopausal women. *Drugs R D*. 2014;14(2):125-132.

28. Key P. Prasterone (Intravaginal) for dyspareunia. *Menopause*. 2016;23(3):243-256.
29. Labrie F, Derogatis L, Archer DF, et al. Effect of intra-vaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. *J Sex Med*. 2015;12(12):2401-2412.
30. Chitrapu P, Karaviti L. Administration of exogenous testosterone as a new kind of sexual abuse: broadening the differential for clitoromegaly. *Endocrine Practice*. 2018;24(suppl 1):162-163 abstr.
31. Velten J. The dual control model of sexual response: relevance of sexual excitation and sexual inhibition for sexual function. *Curr Sex Health Rep*. 2017;9:90-97.
32. Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. *J Sex Med*. 2013;10(7):1807-1815.
33. Althof S, DeRogatis LR, Clayton AH. Changes in sexual functioning in the bremelanotide RECONNECT study. *J Womens Health*. 2017;26:A13.
34. Safarinejad MR, Hosseini SY, Asgari MA, et al. A randomized, double blind, placebo controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. *BJU Int*. 2010;106(6):832-839.
35. Patel K, Allen S, Haque MN, et al. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. *Ther Adv Psychopharmacol*. 2016;6(2):99-144.
36. Kuate C, Gélisse P, Baldy-Moulinier M, Crespel A. Bupropion-induced epileptic seizures. *Rev Neurol (Paris)*. 2004;160(6-7):701-703.
37. Clayton AH, Croft HA, Yuan J, et al. Safety of flibanserin in women treated with antidepressants: a randomized, placebo-controlled study. *J Sex Med*. 2018;15(1):43-51.
38. Burghardt KJ, Gardner KN. Sildenafil for SSRI-induced sexual dysfunction in women. *Curr Psychiatry*. 2013;12(4):29-33.
39. Yang CC, Cao YY, Guan QY, et al. Influence of PDE5 inhibitor on MRI measurement of clitoral volume response in women with FSAD: a feasibility study of a potential technique for evaluating drug response. *Int J Impot Res*. 2008;20(1):105-110.
40. Bottari A, Belcaro G, Ledda A, et al. Lady Prelox® improves sexual function in post-menopausal women. *Panminerva Med*. 2012;54(1 suppl 4):3-9.
41. Bottari A, Belcaro G, Ledda A, et al. Lady Prelox® improves sexual function in generally healthy women of reproductive age. *Minerva Ginecol*. 2013;65(4):435-444.
42. Stanislavov R, Rohdewald P. PACR (pine bark extract, L-arginine, L-citrulline, rose hip extract) improves emotional, physical health and sexual function in peri-menopausal women. *J Women's Health Care*. 2014;3(6).
43. de Jong TR, Menon R, Bludau A, et al. Salivary oxytocin concentrations in response to running, sexual self-stimulation, breastfeeding and the TSST: the Regensburg Oxytocin Challenge (ROC) study. *Psychoneuroendocrinology*. 2015;62:381-388.
44. Veening JG, De Jong TR, Waldinger MD, et al. The role of oxytocin in male and female reproductive behavior. *Eur J Pharmacol*. 2015;753:209-228.
45. Behnia B, Heinrichs M, Bergmann W, et al. Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples. *Horm Behav*. 2014;65(3):308-318.
46. Worsley R, Santoro N, Miller KK, et al. Hormones and female sexual dysfunction: beyond estrogens and androgens—findings from the Fourth International Consultation on Sexual Medicine. *J Sex Med*. 2016;13(3):283-290.
47. Abedi P, Najafian M, Yaralizadeh M, Namjoyan F. Effect of fennel vaginal cream on sexual function in postmenopausal women: a double blind randomized controlled trial. *J Med Life*. 2018;11(1):24-28.
48. Goldstein SW, Gonzalez JR, Gagnon C, Goldstein I. Peripheral female genital arousal as assessed by thermography following topical genital application of alprostadil vs placebo arousal gel: a proof-of-principle study without visual sexual stimulation. *Sex Med*. 2016;4(3):e166-e175.
49. Goldstein S, Kukkonen T, Monsef A, Goldstein I. A double-blind, placebo-controlled, 2-way crossover study using thermography to assess the pharmacodynamics of sildenafil cream, 3.6% in healthy women. *J Sex Med*. 2020;17(1 suppl 1):S69.
50. Liao Q, Zhang M, Geng L, et al. Efficacy and safety of alprostadil cream for the treatment of female sexual arousal disorder: a double blind, placebo controlled study in Chinese population. *J Sex Med*. 2008;5(8):1923-1931.
51. Zhang M, Liao Q, Yao C, et al. Multicenter randomized, double-blind, placebo-controlled trial of prostaglandin E1 cream for female sexual arousal disorder. *Beijing Da Xue Xue Bao Yi Xue Ban*. 2010;42(6):727-733.
52. Ferguson DM, Hosmane B, Heiman JR. Randomized, placebo-controlled, double-blind, parallel design trial of the efficacy and safety of Zestra in women with mixed desire/interest/arousal/orgasm disorders. *J Sex Marital Ther*. 2010;36(1):66-86.
53. Krychman M, Kellogg S, Damaj B, Hachicha M. Female arousal and orgasmic complaints in a diverse cancer population treated with Zestra: a topical applied blend of botanical oils. *J Sex Med*. 2015;12:4-5.
54. Nummenmaa L, Suvilehto JT, Glerean E, et al. Topography of human erogenous zones. *Arch Sex Behav*. 2016;45(5):1207-1216.